Publications by authors named "S V Sitnikova"
Introduction: Immuno-oncology (IO) research relies heavily on murine syngeneic tumor models. However, whilst the average age for a cancer diagnosis is 60 years or older, for practical purposes the majority of preclinical studies are conducted in young mice, despite the fact that ageing has been shown to have a significant impact on the immune response.
Methods: Using aged (60-72 weeks old) mice bearing CT26 tumors, we investigated the impact of ageing on tumor growth as well as the immune composition of the tumor and peripheral lymphoid organs.
Purpose: To assess the effectiveness of the medicine Ophtalmoferon (eye drops) in the treatment of conjunctivitis of mixed aetiology in patients with first-time tuberculosis (TB) and human immunodeficiency virus (HIV) infection, who have been treated at the Clinical Anti-tuberculosis Hospital No. 4.
Material And Methods: The study included 60 patients (42 men and 18 women with mean age of 41.
Article Synopsis
- Immuno-oncology treatments have become standard for many cancers, but only a few patients see lasting benefits, highlighting the need for biomarkers to predict which patients will respond.
- Researchers developed a new non-terminal biopsy method using fine needle aspiration to sample tumor tissue in mice without sacrificing them, allowing for repeated analysis.
- This innovative technique enables linking tumor microenvironment biomarkers to treatment outcomes, enhancing preclinical research while minimizing animal use.
Article Synopsis
- Combining PD-1 blockade with CTLA4 inhibition can be more effective but often leads to serious side effects, limiting how much CTLA4 treatment can be given.
- MEDI5752 is a new type of bispecific antibody that selectively targets PD-1 activated T cells and has a unique mechanism that reduces the necessary dose for a therapeutic effect, including rapid degradation of PD-1.
- Early results show that MEDI5752 can enhance tumor targeting and activity, leading to positive responses in patients with advanced solid tumors, highlighting its potential as an improved cancer immunotherapy strategy.
Pubertal and prepubertal rats were exposed to single (at doses of 0.1, 1, 10 Gy) or fractionated (at total doses of 1 and 10 Gy) X-ray irradiation. It has been shown that the irradiation is accompanied by the one-way phasic changes of thyroid and genital glands independently of the animals' puberty.
View Article and Find Full Text PDF